DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Qualaquin (Quinine Sulfate) - Summary



Qualaquin (quinine sulfate) is an antimalarial drug.

Qualaquin is supplied for oral administration as capsules containing 324 mg of the active ingredient quinine sulfate USP, equivalent to 269 mg free base.

Treatment of Malaria:
Qualiquin is indicated only for treatment of uncomplicated Plasmodium falciparum malaria. Quinine sulfate has been shown to be effective in geographical regions where resistance to chloroquine has been documented (See CLINICAL STUDIES).

Qualiquin oral capsules are not approved for patients with severe or complicated P. falciparum malaria.

Qualiquin oral capsules are not approved for prevention of malaria.

Qualiquin oral capsules are not approved for the treatment or prevention of nocturnal leg cramps.

See all Qualaquin indications & dosage >>


Media Articles Related to Qualaquin (Quinine)

First Malaria Vaccine Approved by EU Regulators
Source: Medscape Medical News Headlines [2015.07.24]
Mosquirix, which offers modest protection against the deadly disease, now awaits review by the World Health Organization.
International Approvals

Medical News Today: European drugs regulators approve world's first malaria vaccine
Source: Featured Health News from Medical News Today [2015.07.24]
The European Medicines Agency recommend the use of the world's first malaria vaccine among children aged 6 weeks to 17 months in Africa - where the disease is most prevalent.

European drugs regulators approve world's first malaria vaccine
Source: Immune System / Vaccines News From Medical News Today [2015.07.24]
The European Medicines Agency recommend the use of the world's first malaria vaccine among children aged 6 weeks to 17 months in Africa - where the disease is most prevalent.

Testing for malaria reduces overprescription by more than 70 percent
Source: Medical Devices / Diagnostics News From Medical News Today [2015.07.23]
Introducing rapid diagnostic tests in Ugandan drug shops improves treatment of malaria patientsUsing malaria rapid diagnostic tests in registered drug shops in a highly endemic region in Uganda...

Antimalaria treatment that targets a blood protein shows promise
Source: Biology / Biochemistry News From Medical News Today [2015.07.21]
Treatment that disables a blood protein the malaria parasite needs to survive in the host's body wipes out the disease in humanized mice in 3 days, reveals a new study.

more news >>

Published Studies Related to Qualaquin (Quinine)

Quinine-induced thrombocytopenia: drug-dependent GPIb/IX antibodies inhibit megakaryocyte and proplatelet production in vitro. [2011.06.02]
The development of immune cytopenias is a well-recognized side effect of many drugs...

Limited ability of Plasmodium falciparum pfcrt, pfmdr1, and pfnhe1 polymorphisms to predict quinine in vitro sensitivity or clinical effectiveness in Uganda. [2011.02]
Quinine is a standard drug for treating severe malaria in Africa, and it is also increasingly used to treat uncomplicated disease. However, failures of quinine therapy are common, and it is unknown if failures in Africa are due to drug resistance... Our data suggest that quinine sensitivity is a complex trait and that known polymorphisms in pfcrt, pfmdr1, and pfnhe1, while associated with quinine sensitivity, are not robust markers for quinine resistance.

Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. [2010.11.13]
BACKGROUND: Severe malaria is a major cause of childhood death and often the main reason for paediatric hospital admission in sub-Saharan Africa. Quinine is still the established treatment of choice, although evidence from Asia suggests that artesunate is associated with a lower mortality. We compared parenteral treatment with either artesunate or quinine in African children with severe malaria... INTERPRETATION: Artesunate substantially reduces mortality in African children with severe malaria. These data, together with a meta-analysis of all trials comparing artesunate and quinine, strongly suggest that parenteral artesunate should replace quinine as the treatment of choice for severe falciparum malaria worldwide. FUNDING: The Wellcome Trust. Copyright (c) 2010 Elsevier Ltd. All rights reserved.

Efficacy and safety of artemether-lumefantrine compared with quinine in pregnant women with uncomplicated Plasmodium falciparum malaria: an open-label, randomised, non-inferiority trial. [2010.11]
BACKGROUND: Malaria in pregnancy is associated with maternal and fetal morbidity and mortality. In 2006, WHO recommended use of artemisinin-based combination treatments during the second or third trimesters, but data on efficacy and safety in Africa were scarce. We aimed to assess whether artemether-lumefantrine was at least as efficacious as oral quinine for the treatment of uncomplicated falciparum malaria during the second and third trimesters of pregnancy in Mbarara, Uganda... INTERPRETATION: Artemisinin derivatives are not inferior to oral quinine for the treatment of uncomplicated malaria in pregnancy and might be preferable on the basis of safety and efficacy. FUNDING: Medecins Sans Frontieres and the European Commission. Copyright (c) 2010 Elsevier Ltd. All rights reserved.

Comparison of quinine and rabeprazole with quinine monotherapy in the treatment of uncomplicated falciparum malaria. [2010.09]
OBJECTIVE: This study was conducted to assess the effect of combination treatment of quinine and rabeprazole in the treatment of uncomplicated Plasmodium falciparum malaria... CONCLUSION: The study results suggest that addition of rabeprazole to quinine regimen resulted in an increase in the parasite elimination rate, which may be helpful in reducing the duration of treatment and increasing patient compliance.

more studies >>

Clinical Trials Related to Qualaquin (Quinine)

Comparative Study of Quinine Sulfate in Healthy Patients and in Patients With Renal Impairment [Recruiting]
The effects of mild or moderate renal impairment (creatinine clearance 30 to 50 ml/min or >50 to 80 ml/min, respectively) on the pharmacokinetic profile of quinine and its active metabolite, 3'-hydroxyquinine, will be investigated. Safety and tolerability in healthy subjects versus those with mild to moderate renal impairment will be compared, as well.

Impact of Artemisinin-based Combination Therapy and Quinine on Treatment Failure and Resistance in Uncomplicated Malaria [Recruiting]
This is a bi-centric phase IIIb, randomized, open label, 3-arm clinical trial performed to investigate the impact of retreatment with an Artemisinin-Based Combination (ACT), for example Arthemeter-Lumefantrine (AL) in Uganda (Ug) and artesunate-amodiaquine (ASAQ) in RDCongo, on malaria incidence and its potential selection of resistant strains.

Patients will be followed-up for efficacy and safety during 42 days after treatment with the first line therapy recommended by the national authorities(arthemeter-lumefantrine in Uganda and artesunate-amodiaquine in RDCongo) and retreated the patients either with the same ACT or an other ACT or oral Quinine + clyndamicin.

The investigators hypothesize that (re)treatment with the first line ACT treatment beyond 14 days is as efficacious as any other rescue treatment, without the risk of selecting drug resistant strains.

Influence of Probenecid and Quinine on the Pharmacokinetics of Azidothymidine [Completed]
Part I studies the effect of quinine on how zidovudine (AZT) is used by the body and eliminated through the kidneys in HIV infected patients. Part II studies the effect of probenecid and quinine on the same aspects.

Because AZT leaves the bloodstream quickly, patients must take the drug frequently to keep adequate amounts in their bodies. Probenecid and quinine may slow down the rate at which AZT leaves the body. Therefore, taking these drugs along with AZT may reduce the amount of AZT needed for treatment.

Efficacy of Intrarectal Versus Intravenous Quinine for the Treatment of Childhood Cerebral Malaria [Active, not recruiting]
Cerebral malaria is the most lethal complication of P. falciparum infection with a mortality rate between 5 and 40%. Intravenous quinine remains the recommended treatment for cerebral malaria. However its administration is often not feasible due to lack of simple equipment or trained staff. When referral is not possible, a viable alternative is needed. The intrarectal route is of interest in children since it is painless and simple. Studies of the efficacy of intrarectal quinine in the treatment of cerebral malaria are limited. The study aims to establish the efficacy of intrarectal quinine in the treatment of childhood cerebral malaria.

Treatment of Malaria With Quinine Plus Sulfadoxine-Pyrimethamine [Completed]
Quinine remains the treatment of choice of hospitalised malaria cases. The long treatment duration of 7 days, and adverse reactions often hamper its adequate use. Reducing the treatment duration by adding sulfadoxine-pyrimethamine may enhance compliance and reduce side effects.

The efficacy of a 3-day treatment of quinine plus sulfadoxine-pyrimethamine for the treatment of hospitalised, uncomplicated malaria cases was assessed.

more trials >>

Reports of Suspected Qualaquin (Quinine) Side Effects

OFF Label USE (7)Hypoacusis (2)Hearing Impaired (2)Pruritus (1)Tinnitus (1)Deafness (1)Pruritus Generalised (1)Oedema Peripheral (1)Ecchymosis (1)Nervousness (1)more >>

Page last updated: 2015-07-24

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015